Sign In
Buy NTLA
$12.02
+0.0800 (+0.670%)
At Close: Aug 10, 2026
Can NTLA's In Vivo Pipeline Drive Long-Term Growth Amid Rivalry?
11:01am, Friday, 28'th Nov 2025
Intellia advances in vivo pipeline with lonvo-z through its pivotal HAELO study, eyeing mid-2026 data and a potential 2026 filing to propel growth.
BEAM vs. NTLA: Which Gene Editing Stock Holds More Potential?
09:15am, Thursday, 27'th Nov 2025
Beam's broad early-stage pipeline and recent study progress take center stage as investors weigh its potential against rival NTLA's prospects.
AXQ Capital LP Buys New Position in Intellia Therapeutics, Inc. $NTLA
03:34am, Tuesday, 25'th Nov 2025
AXQ Capital LP acquired a new position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The
What Moved Markets This Week
06:50am, Saturday, 22'nd Nov 2025
Listen on the go! A daily podcast of Wall Street Breakfast will be available by 8:00 a.m.
NTLA Declines 67% in a Month: Should You Buy, Sell or Hold the Stock?
11:20am, Friday, 21'st Nov 2025
Intellia sinks 67% in a month after a clinical hold on nex-z and mixed third-quarter results, raising questions about its pipeline outlook and near-term direction.
2 Beaten-Down Stocks to Avoid Right Now
09:35am, Saturday, 15'th Nov 2025
Intellia Therapeutics and Sarepta Therapeutics have hit serious setbacks potentially linked to their treatments. Both biotechs have lost market value as a result, but both still seem too risky to cons
Can NTLA Stock Bounce Back in 2026 After Recent Pipeline Setbacks?
10:01am, Friday, 14'th Nov 2025
Intellia faces FDA clinical holds on key ATTR studies as it readies crucial HAE data in 2026, making lonvo-z pivotal for its near-term outlook.
CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based thera
Intellia Therapeutics Presents Positive Pooled Phase 1/2 Data of Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema
05:13pm, Saturday, 08'th Nov 2025
CAMBRIDGE, Mass., Nov. 08, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ: NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ther
Intellia Q3 Loss Narrower Than Expected, Stock Down on Pipeline Trouble
11:01am, Friday, 07'th Nov 2025
Despite a narrower Q3 loss, NTLA stock plunges after pulling nex-z milestone guidance amid FDA scrutiny in amyloidosis patients.
2 Small-Cap Stocks With Far More Upside Than Any "Magnificent Seven" Stock, According to Wall Street
08:45am, Friday, 07'th Nov 2025
Iovance Biotherapeutics and Intellia Therapeutics are two innovative small-cap biotechs. Both companies face serious issues despite Wall Street's high price targets for them.
Intellia Therapeutics, Inc. (NTLA) Q3 2025 Earnings Call Transcript
05:46am, Friday, 07'th Nov 2025
Intellia Therapeutics, Inc. ( NTLA ) Q3 2025 Earnings Call November 6, 2025 6:00 PM EST Company Participants Jason Fredette John Leonard - President, CEO & Director Edward Dulac - Executive Vice Presi
Intellia Therapeutics, Inc. (NTLA) Reports Q3 Loss, Misses Revenue Estimates
06:21pm, Thursday, 06'th Nov 2025
Intellia Therapeutics, Inc. (NTLA) came out with a quarterly loss of $0.92 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $1.34 per share a year ago.
AlphaQuest LLC Sells 29,619 Shares of Intellia Therapeutics, Inc. $NTLA
03:59am, Monday, 03'rd Nov 2025
AlphaQuest LLC reduced its position in Intellia Therapeutics, Inc. (NASDAQ: NTLA) by 57.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Ex
Meet the Beaten-Down Biotech Stock Cathie Wood Loves and Wall Street Says May Soar More Than 130%
09:25am, Sunday, 02'nd Nov 2025
Intellia Therapeutics is featured in Cathie Wood's portfolio and has a high Wall Street price target. The company's leading candidates look somewhat promising, but one of them just hit a major setback
